CEPHEID (CPHD) has risen sharply, recording gains of 8.31% in the past 4 weeks. However, the stock has corrected -0.45% in the past 1 week, providing a good buying opportunity on dips. On a relative basis, the stock has outperformed the S&P 500 by 7.9% in the past 4 weeks, but has underperformed the S&P 500 in the past 1 week.
Cepheid is up 32.58% in the last 3-month period. Year-to-Date the stock performance stands at -2.63%. The stock has recorded a 20-day Moving Average of 0.68% and the 50-Day Moving Average is 8.96%.
CEPHEID (NASDAQ:CPHD): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $35.01 and $34.51 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $35.93. The buying momentum continued till the end and the stock did not give up its gains. It closed at $35.57, notching a gain of 1.37% for the day. The total traded volume was 1,015,266 . The stock had closed at $35.09 on the previous day.
Also, Jefferies maintains their rating on the shares of CEPHEID (NASDAQ:CPHD). The current rating of the shares is Hold. Equity Analysts at the Firm raises the price target to $34 per share from $28 per share. The rating by the firm was issued on August 17, 2016.
Cepheid is a molecular diagnostics company. The Company develops, manufactures and markets fully-integrated systems for testing in the clinical market and non-clinical markets. Its systems enable molecular testing for organisms and genetic-based diseases. Molecular testing involves various time-intensive steps, including sample preparation, DNA amplification and detection. The Companys systems integrate these steps and analyze biological samples in test cartridges. Its primary offering is the GeneXpert system, which integrates sample preparation in addition to DNA amplification and detection, serves reference laboratories and hospital central laboratories to satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also offers the SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample.